Yuhan Pharmaceutical Collaborates with Cyclica to Enhance Drug Development Utilizing AI-Integrated Drug Discovery Platform

 Yuhan Pharmaceutical Collaborates with Cyclica to Enhance Drug Development Utilizing AI-Integrated Drug Discovery Platform

Yuhan Pharmaceutical Collaborates with Cyclica to Enhance Drug Development Utilizing AI-Integrated Drug Discovery Platform

Shots:

  • Cyclica to receive up front and milestones on completion of specific objectives. Yuhan will leverage Cyclica’s AI integrated drug discovery platform, Ligand Design and Ligand Express in two separate R&D programs
  • Yuhan enhance its drug development efforts by utilizing AI integrated drug discovery platform across multiple therapeutic areas to develop novel therapies targeting Yuhan’s R&D interest
  • Cyclica’s Ligand Design and Ligand Express provides AI-augmented platform to design advanced lead-like molecules, minimizing unwanted off-target effects by providing a holistic understanding of its biology and structural pharmacogenomics

Click here to­ read full press release/ article | Ref: Business wire | Image: Cyclica

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post